Lantheus Buys Rights To Fibroblast Activation Protein Targeting Imaging Biomarker

• Lantheus Holdings Inc (NASDAQ: LNTH) has acquired the exclusive worldwide rights to develop, manufacture and commercialize NTI-1309, a PET oncology imaging agent from Noria Therapeutics Inc.

• NTI-1309 targets fibroblast activation protein (FAP), a target with potential broad imaging applicability and targeting oncology implications.

• FAP is overexpressed in the tumor microenvironment, specifically in tumor-associated fibroblasts, which modulates tumor progression and immune response.

• Under terms of the agreement, Noria will drive the early clinical development of NTI-1309.

• Upon completing the Phase 1 study, NTI-1309 will be integrated into Lantheus's portfolio of imaging biomarkers.

• The transaction's terms include an upfront license and development fee to Noria, certain milestone payments, and royalties if NTI-1309 is commercialized.

• Price Action: LNTH shares are up 10.1% at $21.69 in market trading hours on the last check Tuesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Forma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease Study

• Tiziana To Treat Multiple Sclerosis Patient With Nasal Administration of Foralumab

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.